Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Dec;48(12):887-92.
doi: 10.1007/s00234-006-0142-8. Epub 2006 Sep 16.

Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy

Affiliations
Case Reports

Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy

A Ozkan et al. Neuroradiology. 2006 Dec.

Abstract

Introduction: Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities.

Method: We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome.

Results: The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome.

Conclusion: Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.

PubMed Disclaimer

References

    1. Neurology. 1999 Apr 12;52(6):1285-8 - PubMed
    1. Clin Exp Nephrol. 2003 Mar;7(1):63-6 - PubMed
    1. Neuroradiology. 2005 Sep;47(9):652-6 - PubMed
    1. Leuk Res. 2007 Apr;31(4):573-4 - PubMed
    1. Pediatr Radiol. 2005 Jul;35(7):722-7 - PubMed

Publication types

LinkOut - more resources